These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16401732)

  • 1. What we can learn from open-label extensions of randomized clinical trials.
    Cummings JL
    Arch Neurol; 2006 Jan; 63(1):18-9. PubMed ID: 16401732
    [No Abstract]   [Full Text] [Related]  

  • 2. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
    Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ
    Arch Neurol; 2006 Jan; 63(1):49-54. PubMed ID: 16401736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine in the treatment of dementia.
    Maggiore C; Locatelli L; Grandi FC; Pizzolato G;
    Neuroepidemiology; 2007; 28(2):118-9. PubMed ID: 17409774
    [No Abstract]   [Full Text] [Related]  

  • 4. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT; Pejović V; Miller ML; Graham SM
    Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Little behavior improvement with memantine].
    Potz-Biedermann C
    Med Monatsschr Pharm; 2005 Nov; 28(11):413-4. PubMed ID: 16309030
    [No Abstract]   [Full Text] [Related]  

  • 11. [The challenge of Alzheimer dementia].
    Pharm Unserer Zeit; 2003; 32(1):77. PubMed ID: 12577765
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
    Gauthier S; Loft H; Cummings J
    Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine (Ebixa) in clinical practice - results of an observational study.
    Calabrese P; Essner U; Forstl H
    Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
    Leroi I; Overshott R; Byrne EJ; Daniel E; Burns A
    Mov Disord; 2009 Jun; 24(8):1217-21. PubMed ID: 19370737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
    Maidment ID; Fox CG; Boustani M; Rodriguez J; Brown RC; Katona CL
    Ann Pharmacother; 2008 Jan; 42(1):32-8. PubMed ID: 18056833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Another perspective on the memantine graphs: clinical vs. statistical significance.
    Davis S
    Med Health R I; 2005 Jan; 88(1):12-4; discussion 14. PubMed ID: 15779549
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antibodies, antihypertensive drugs, antioxidants. Can they prevent Alzheimer disease?].
    MMW Fortschr Med; 2003 Aug; 145(33-34):60. PubMed ID: 14526584
    [No Abstract]   [Full Text] [Related]  

  • 19. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
    Ferris S; Schneider L; Farmer M; Kay G; Crook T
    Int J Geriatr Psychiatry; 2007 May; 22(5):448-55. PubMed ID: 17117395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease.
    Rabins PV; Lyketsos CG
    Nat Clin Pract Neurol; 2006 Nov; 2(11):578-9. PubMed ID: 17057739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.